拟钙剂作为血管亲和性药物的新作用。

The new role of calcimimetics as vasculotropic agents.

作者信息

Al-Aly Ziyad

机构信息

Division of Nephrology, Saint Louis Veterans Affairs Medical Center, Saint Louis, Missouri, USA.

出版信息

Kidney Int. 2009 Jan;75(1):9-12. doi: 10.1038/ki.2008.563.

DOI:10.1038/ki.2008.563

PMID:19092812

Abstract

The discovery of the calcium-sensing receptor (CaSR) and the development of calcimimetics have provided new insights into calcium homeostasis and new therapeutic opportunities for parathyroid-related disorders. However, the CaSR is also implicated in various other cellular processes, and the translational applications of calcimimetics may not be exclusively calcium-centric. Koleganova et al. describe a novel role for calcimimetics as vasculotropes, which provides the impetus for further studies to characterize their effects on vascular biology.

摘要

钙敏感受体（CaSR）的发现以及拟钙剂的研发为钙稳态提供了新的见解，并为甲状旁腺相关疾病带来了新的治疗机遇。然而，CaSR也参与了各种其他细胞过程，且拟钙剂的转化应用可能并非仅以钙为中心。科列加诺娃等人描述了拟钙剂作为血管亲和剂的一种新作用，这为进一步研究其对血管生物学的影响提供了动力。